Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
Seifert, K; Perez-Victoria, FJ; Stettler, M; Sánchez-Cañete, MP; Castanys, S; Gamarro, F; Croft, SL; (2007) Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. International journal of antimicrobial agents, 30 (3). pp. 229-35. ISSN 0924-8579 DOI: 10.1016/j.ijantimicag.2007.05.007
Miltefosine (hexadecylphosphocholine) is the first oral antileishmanial drug. In this study, we addressed the question whether miltefosine-resistant Leishmania donovani promastigotes transform to miltefosine-resistant amastigotes. A promastigote line, M-mutR, showed defective internalisation of miltefosine owing to mutations in LdMT, similar to previously described resistant lines. M-mutR parasites were infective to macrophages in vitro as well as in BALB/c mice in vivo. There was good correlation of in vitro resistance indices between promastigotes and intracellular amastigotes. Most importantly, M-mutR parasites retained the resistant phenotype in vivo, with no decrease of hepatic burden in BALB/c mice following miltefosine treatment up to 30mg/kg (ca. 90% inhibition in wild-type infections). No cross-resistance to other antileishmanial drugs was observed in M-mutR amastigotes.
|Faculty and Department:||Faculty of Infectious and Tropical Diseases > Dept of Immunology and Infection|
|Research Centre:||Antimicrobial Resistance Centre (AMR)
|Web of Science ID:||249137300006|
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Actions (login required)